All The Claims

1. A pressure powder metallurgy process for creating a rhenium based alloy, the process comprising the steps of:
mixing a first powder and a second powder to provide a mixture, the first powder comprising rhenium and the second powder comprising cobalt, chromium, and manganese, wherein the mixture comprises at least 50% by atomic percent of rhenium and at least 25% by atomic percent of cobalt, chromium, and manganese; and
heating the mixture under pressure to fuse the rhenium with the second powder so as to form the rhenium based alloy.
2. A process for creating an alloy as set forth in claim 1, further comprising:
heating the mixture to a temperature between approximately 1000\xb0 C. and 1800\xb0 C.
3. A process for creating an alloy as set forth in claim 2, further comprising:
heating the mixture under a pressure of between approximately 250 psi and 14000 psi.
4. A process for creating an alloy as set forth in claim 3, whereby the second powder further comprises one or more materials selected from the group consisting of nickel and ceramic.
5. A process for creating an alloy as set forth in claim 3, whereby the second powder further comprises nickel.
6. A process for creating an alloy as set forth in claim 3, whereby the second power further comprises silicon carbide and nickel.

The claims below are in addition to those above.
All refrences to claims which appear below refer to the numbering after this setence.

1. A multiple pole arc-fault circuit breaker comprising:
a first pole assembly and a second pole assembly, at least one of the first pole assembly and the second pole assembly having a trip mechanism;
a microprocessor electrically coupled to the first pole assembly and to the second pole assembly, the microprocessor being operative to
in response to receiving a single test signal, perform electrical tests for both the first pole assembly and the second pole assembly, and
in response to successful completion of the electrical tests, actuate the trip mechanism; and

a single test button mounted to the housing and including a single test position for sending the single test signal, the electrical tests being initiated in response to receiving the single test signal when the test button is positioned in the single test position.
2. The multiple pole arc-fault circuit breaker of claim 1, wherein the single test button is mechanically positioned in the first pole assembly.
3. The multiple pole arc-fault circuit breaker of claim 1, wherein the single test button includes only two mechanical positions, the two mechanical positions being the single test position and an off position.
4. The multiple pole arc-fault circuit breaker of claim 1, further comprising
a circuit board for mounting the microprocessor, and
a spring mounted in the first pole assembly, the spring having a first end proximate the single test button and a second end connected to the circuit board, the first end being movable between an open electrical position and a closed electrical position.
5. The multiple pole arc-fault circuit breaker of claim 4, wherein the closed electrical position of the spring is achieved in response to moving the single test button in the single test position, the open electrical position of the spring corresponding to an off position of the single test button.
6. The multiple pole arc-fault circuit breaker of claim 4, wherein the second end of the spring is electrically coupled to one of a first voltage line, a second voltage line, and a neutral line.
7. The multiple pole arc-fault circuit breaker of claim 1, wherein the electrical tests includes one or more of a line current response test, a voltage monitor circuits test, a ground fault circuit test, and a microprocessor diagnostics test.
8. The multiple pole arc-fault circuit breaker of claim 1, further comprising
a movable member positioned near the single test button and being electrically conductive, the movable member having a first end coupled to a voltage line and a second end movable between an electrically coupled position and an electrically uncoupled position, the electrically coupled position corresponding to the single test position of the single test button; and
a fixed member having a primary end positioned near the second end of the movable member such that the primary end is in contact with the second end of the movable member in the electrically coupled position, the fixed member having a secondary end electrically coupled to a line power connection.
9. The multiple pole arc-fault circuit breaker of claim 1, further comprising a first housing for enclosing the first pole assembly and a second housing for enclosing the second pole assembly, the single test button being mounted to and protruding in part from the first housing.
10. The multiple pole arc-fault circuit breaker of claim 1, wherein the single test button includes a protruding part extending away from a housing of the first pole assembly, the single test button being moved between an off position and the single test position by pushing the protruding part towards the housing.
11. A multiple pole arc-fault circuit breaker comprising:
a first pole assembly having a first trip mechanism;
a second pole assembly coupled to the first pole assembly and having a second trip mechanism;
at least one housing for enclosing the first pole assembly and the second pole assembly;
a microprocessor communicatively coupled to the first trip mechanism and the second trip mechanism, the microprocessor being operative to
perform a plurality of tests for determining failure conditions associated with the first pole assembly and the second pole assembly, and
in response to successful completion of the tests, actuate at least one of the first trip mechanism and the second trip mechanism;

a single test button mounted to the housing and having a protruding part extending outwards from a surface of the housing, the single test button being movable between an off position and a test position by pressing the protruding part; and
a pair of contacts mounted in the housing near the single test button, the pair of contacts being forced in electrical contact with each other when the single test button is moved to the test position, the pair of contacts causing a test signal to be sent to a single pin of the microprocessor to initiate the plurality of tests.
12. The multiple pole arc-fault circuit breaker of claim 11, wherein a first one of the pair of contacts is electrically coupled to one of a first voltage line, a second voltage line, and a neutral line.
13. The multiple pole arc-fault circuit breaker of claim 11, wherein the microprocessor is mounted on a circuit board that is attached to the housing.
14. The multiple pole arc-fault circuit breaker of claim 11, wherein the failure conditions include detecting one or more of an arc-fault condition and a ground fault condition.
15. The multiple pole arc-fault circuit breaker of claim 11, wherein the plurality of tests includes one or more of a line current response test, a voltage monitor circuits test, and a microprocessor diagnostics test.
16. The multiple pole arc-fault circuit breaker of claim 11, wherein the microprocessor is further operative to perform tests associated with the first pole assembly first and, upon successful completion of the tests associated with the first pole assembly, perform tests associated with the second pole assembly.

1-20. (canceled)
21. A method for resolving invoice obligations, comprising:
providing at least one sales invoice, wherein each sales invoice comprises a credit value,
providing at least one purchase invoice, wherein each purchase invoice comprises a debit value, and
offsetting at least part of the debit value of a purchase invoice with at least part of the credit value of a sales invoice.
22. The method of claim 21, wherein the at least one sales invoice and the at least one purchase invoice form an invoice chain.
23. The method of claim 22, wherein the invoice chain is a complete chain.
24. The method of claim 22, wherein the invoice chain is a disparity chain.
25. The method of claim 22, wherein at least one determined optimal condition is utilized to determine an optimal starting point for the invoice chain.
26. The method of claim 2, wherein the invoice chain comprises an optimal invoice chain.
27. The method of claim 21, wherein at least one of the at least one sales invoice is provided by a seller, a customer or a combination thereof.
28. The method of claim 21, wherein at least one of the at least one purchase invoice is provided by a customer.
29. The method of claim 21, further comprising issuing at least one new invoice or a new balance of a partially offset invoice if the offsetting results in at least one partial fulfillment of an original invoice.
30. The method of claim 21, wherein the step of offsetting accounts for at least one currency denomination, at least one set of invoice terms and conditions or a combination thereof.
31. A method for resolving invoice obligations, comprising
providing at least one seller having at least one sales invoice,
providing at least one customer having at least one sales invoice and at least one purchase invoice, wherein at least one of the at least one sales invoice and at least one of the at least one purchase invoice forms an invoice chain; and
offsetting the at least one sales invoice of the seller with at least one sales invoice of the customer, at least one purchase invoice or a combination thereof.
32. The method of claim 31, wherein the invoice chain is a complete chain.
33. The method of claim 31, wherein the invoice chain is a disparity chain.
34. The method of claim 31, wherein at least one determined optimal condition is utilized to determine an optimal starting point for the invoice chain.
35. The method of claim 31, wherein the invoice chain comprises an optimal invoice chain.
36. A system for resolving invoice obligations, comprising:
an executable code for intelligently determining an invoice chain comprising at least one purchase invoice having a debit value and at least one sales invoice having a credit value and offsetting the debit value with the credit value,
a medium for executing the executable code,
a display device, and
an interaction tool for executing the executable code, wherein a user utilizes the interaction tool to execute the executable code.
37. The system of claim 36, wherein the medium for executing the executable code comprises a computer processor, a server system, a network system, a web-based system, the internet or a combination thereof.
38. The system of claim 36, wherein the display device comprises a computer monitor, a handheld device monitor, a television monitor, a paper or a combination thereof.
39. The system of claim 36, wherein the interaction tool comprises a series of user presets, a mouse, a keyboard, voice recognition software, touch recognition software; an application interface; integrated software or a combination thereof.
40. A software package, comprising:
an executable code for intelligently determining an invoice chain comprising at least one sales invoice having a credit value and at least one purchase invoice having a debit value and offsetting the credit value with the debit value, wherein the executable code is stored on a computer readable storage medium.
The claims below are in addition to those above.
All refrences to claims which appear below refer to the numbering after this setence.

1. A method of attenuating expression of TNFR1 mRNA of a subject in need thereof, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising:
a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides;
wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 beginning at nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, or, 2092;
wherein the expression of TNFR1 mRNA is attenuated thereby.
2. The method of claim 1, wherein the subject is a human and the human has dry eye.
3. The method of claim 1, wherein the sense nucleotide strand and the antisense nucleotide strand are connected by a loop nucleotide strand.
4. The method of claim 1, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
5. The method of claim 1, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
6. A method of treating a TNF\u03b1-related ocular condition in a subject in need thereof, comprising:
administering to an eye of the subject a composition beginning at an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and the sense and antisense strands comprise a region of least near-perfect contiguous complementarity of at least 19 nucleotides;
wherein the antisense strand hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:2 comprising nucleotide 124, 328, 387, 391, 393, 395, 406, 421, 423, 444, 447, 455, 459, 460, 467, 469, 470, 471, 475, 479, 513, 517, 531, 543, 556, 576, 587, 588, 589, 595, 601, 602, 611, 612, 651, 664, 667, 668, 669, 677, 678, 785, 786, 788, 791, 792, 804, 813, 824, 838, 843, 877, 884, 929, 959, 960, 961, 963, 964, 965, 970, 973, 974, 1000, 1002, 1013, 1026, 1053, 1056, 1057, 1058, 1161, 1315, 1318, 1357, 1360, 1383, 1393, 1420, 1471, 1573, 1671, 2044, 2045, 2046, 2047, 2048, 2089, 2090, 2091, or, 2092;
wherein the TNF\u03b1-related ocular condition is treated thereby, and wherein the TNF\u03b1-related ocular condition is dry eye, allergic conjunctivitis or ocular inflammation.
7. The method of claim 6, further comprising administering to the eye of the subject a second interfering RNA having a length of 19 to 49 nucleotides and comprising:
a sense nucleotide strand, an antisense nucleotide strand, and the sense and antisense strands comprise a region of least near-perfect contiguous complementarity of at least 19 nucleotides

wherein the antisense strand of the second interfering RNA hybridizes under physiological conditions to a portion of mRNA corresponding to SEQ ID NO:1 comprising nucleotide 297, 333, 334, 335, 434, 470, 493, 547, 570, 573, 618, 649, 689, 755, 842, 844, 846, 860, 878, 894, 900, 909, 910, 913, 942, 970, 984, 1002, 1010, 1053, 1064, 1137, 1162, 1215, 1330, 1334, 1340, 1386, 1393, 1428, 1505, 1508, 1541, 1553, 1557, 1591, 1592, 1593, 1597, 1604, 1605, 1626, 1632, 1658, 1661, 1691, 1794, 1856, 1945, 1946, 1947, 1958, 2022, 2094, 2100, 2121, 2263, 2277, 2347, 2349, 2549, 2578, 2595, 2606, 2608, 2629, 2639, 2764, 2766, 2767, 2769, 3027, 3028, 3261, 3264, 3284, 3313, 3317, 3332, or 3337.
8. The method of claim 6, wherein the sense nucleotide strand and the antisense nucleotide strand are connected by a loop nucleotide strand.
9. The method of claim 6, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
10. The method of claim 6, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
11. The method of claim 6, wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 25 nucleotides in length.
12. The method of claim 6, wherein each strand of the siRNA molecule is independently about 19 nucleotides to about 21 nucleotides in length.
13. A method of attenuating expression of TACE mRNA of a subject, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides and a pharmaceutically acceptable carrier, the interfering RNA comprising:
a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having at least 80% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3\u2032 end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201,
wherein the expression of TACE mRNA is attenuated thereby.
14. The method of claim 13, wherein the interfering RNA is one of an shRNA, an miRNA, or an siRNA.
15. The method of claim 13, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
16. The method of claim 13, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.
17. A method of treating a TNF\u03b1-related condition in a subject in need thereof, comprising:
administering to the subject a composition comprising an effective amount of interfering RNA having a length of 19 to 49 nucleotides, and a pharmaceutically acceptable carrier, wherein
the interfering RNA comprises a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having at least 80% sequence complementarity to, or at least 90% sequence identity with, the penultimate 13 nucleotides of the 3\u2032 end of an mRNA corresponding to any one of SEQ ID NO:3, SEQ ID NO:14-SEQ ID NO:58, and SEQ ID NO:155-SEQ ID NO:201;
wherein the TNF\u03b1-related condition is treated thereby, and wherein the TNF\u03b1-related ocular condition is dry eye, allergic conjunctivitis or ocular inflammation.
18. The method of claim 17, wherein the interfering RNA is one of an shRNA, an miRNA, or an siRNA.
19. The method of claim 17, wherein the composition is administered via an aerosol, buccal, dermal, intradermal, inhaling, intramuscular, intranasal, intraocular, intrapulmonary, intravenous, intraperitoneal, nasal, ocular, oral, otic, parenteral, patch, subcutaneous, sublingual, topical, or transdermal route.
20. The method of claim 17, wherein the interfering RNA is administered via in vivo expression from an expression vector capable of expressing the interfering RNA.